BR0016409A - Processo para avaliar a sensibilidade do hiv a drogas - Google Patents
Processo para avaliar a sensibilidade do hiv a drogasInfo
- Publication number
- BR0016409A BR0016409A BR0016409-7A BR0016409A BR0016409A BR 0016409 A BR0016409 A BR 0016409A BR 0016409 A BR0016409 A BR 0016409A BR 0016409 A BR0016409 A BR 0016409A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- coding sequence
- protease
- recombinant
- molecular clone
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 230000035945 sensitivity Effects 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 8
- 108010010369 HIV Protease Proteins 0.000 abstract 7
- 108091026890 Coding region Proteins 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000012472 biological sample Substances 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 210000004748 cultured cell Anatomy 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
- G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
"PROCESSO PARA AVALIAR A SENSIBILIDADE DO HIV A DROGAS". é descrito um processo para avaliar a sensibilidade de uma variação de HIV proveniente de uma amostra biológica a pelo menos uma droga capaz de inibir a protease do HIV. O processo compreende as etapas de: a) amplificação do ácido nucléico que codifica a protease do HIV proveniente da amostra biológica, para se obter uma seq³ência codificadora da protease do HIV amplificada; b) clonagem da seq³ência codificadora da protease do HIV amplificada em um sítio de restrição único de um clone molecular modificado de HIV, em que o dito clone molecular modificado de HIV é modificado pelo menos através da deleção da seq³ência codificadora da protease e pela substituição da mesma pelo sítio de restrição único, para se obter um clone molecular recombinante de HIV que compreende e expressa a seq³ência codificadora da protease do HIV; c) introdução do clone molecular recombinante do HIV que compreende e expressa a seq³ência codificadora da protease do HIV em células cultivadas, para se obter células transfectadas com o HIV recombinante; d) medida do nível do antígeno p24 do HIV no sobrenadante das células transfectadas com o HIV recombinante tanto na presença quanto na ausência da droga capaz de inibir a protease do HIV. O processo é adequado para qualquer variação de HIV, para variações de HIV-1 ou de HIV-2. São também descrito kits para diagnóstico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99830776A EP1109019A1 (en) | 1999-12-15 | 1999-12-15 | Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease |
| PCT/IT2000/000518 WO2001044508A2 (en) | 1999-12-15 | 2000-12-14 | Method to evaluate the sensitivity of hiv variants to drugs able to inhibit the hiv protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0016409A true BR0016409A (pt) | 2002-08-20 |
Family
ID=8243712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0016409-7A BR0016409A (pt) | 1999-12-15 | 2000-12-14 | Processo para avaliar a sensibilidade do hiv a drogas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030175690A1 (pt) |
| EP (2) | EP1109019A1 (pt) |
| AT (1) | ATE265043T1 (pt) |
| AU (1) | AU2395101A (pt) |
| BR (1) | BR0016409A (pt) |
| CA (1) | CA2393620A1 (pt) |
| DE (1) | DE60010127D1 (pt) |
| RU (1) | RU2002118706A (pt) |
| WO (1) | WO2001044508A2 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0009374D0 (en) * | 2000-04-14 | 2000-05-31 | Glaxo Group Ltd | Phenotyping assay and reagents therefor |
| EP1518557A4 (en) * | 2002-06-28 | 2008-12-03 | Fuso Pharmaceutical Ind | ANTI-HIV AGENTS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571666A (en) * | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| HU226203B1 (en) * | 1996-01-26 | 2008-06-30 | Virco B V B A | Method for determining of the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
-
1999
- 1999-12-15 EP EP99830776A patent/EP1109019A1/en not_active Withdrawn
-
2000
- 2000-12-14 CA CA002393620A patent/CA2393620A1/en not_active Abandoned
- 2000-12-14 RU RU2002118706/15A patent/RU2002118706A/ru unknown
- 2000-12-14 EP EP00987612A patent/EP1242818B1/en not_active Expired - Lifetime
- 2000-12-14 BR BR0016409-7A patent/BR0016409A/pt not_active Application Discontinuation
- 2000-12-14 WO PCT/IT2000/000518 patent/WO2001044508A2/en not_active Ceased
- 2000-12-14 US US10/149,575 patent/US20030175690A1/en not_active Abandoned
- 2000-12-14 DE DE60010127T patent/DE60010127D1/de not_active Expired - Lifetime
- 2000-12-14 AT AT00987612T patent/ATE265043T1/de not_active IP Right Cessation
- 2000-12-14 AU AU23951/01A patent/AU2395101A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001044508A2 (en) | 2001-06-21 |
| ATE265043T1 (de) | 2004-05-15 |
| EP1242818B1 (en) | 2004-04-21 |
| WO2001044508A3 (en) | 2002-01-03 |
| AU2395101A (en) | 2001-06-25 |
| CA2393620A1 (en) | 2001-06-21 |
| DE60010127D1 (de) | 2004-05-27 |
| EP1242818A2 (en) | 2002-09-25 |
| RU2002118706A (ru) | 2004-02-27 |
| US20030175690A1 (en) | 2003-09-18 |
| EP1109019A1 (en) | 2001-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kong et al. | Neuroinflammation generated by HIV-infected microglia promotes dysfunction and death of neurons in human brain organoids | |
| Bushman et al. | Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. | |
| Tang et al. | Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells | |
| Lee et al. | Highly sensitive immuno-CRISPR assay for CXCL9 detection | |
| DK1280898T3 (da) | Modificerede ES-celler og ES-cellespecifikt gen | |
| ATE421999T1 (de) | Nachweis von hiv-1 durch amplifizierung von nukleinsäuren | |
| AR247761A1 (es) | Metodo para producir un polipeptido en una celula hospedante de kluyveromyces, dicha celula hospedante transformada y secuencia a adn empleada | |
| ATE531808T1 (de) | Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna | |
| ES2045932T3 (es) | Procedimiento para la deteccion de secuencias especificas de acidos nucleicos y sus aplicaciones. | |
| UA48936C2 (uk) | Спосіб одержання вірусу курячої анемії (cav) у дволанцюговій формі, рекомбінантна нуклеїнова кислота (варіанти), діагностичний набір (варіанти), вакцинний препарат (варіанти), культура клітин (варіанти), спосіб одержання діагностичного набору (варіанти) | |
| Cao et al. | Label-free and DNAzyme-mediated biosensor with a high signal-to-noise ratio for a lumpy skin disease virus assay | |
| CN113564149A (zh) | 一种三联体融合蛋白及其在病毒自剪切蛋白酶抑制剂活性评估和筛选时的应用 | |
| Nappi et al. | Identification of a novel posttranscriptional regulatory element by using a rev-and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap | |
| ATE513851T1 (de) | Menschliches gen zur fruchtbarkeit entscheidend | |
| Ang et al. | Protein–dna conjugates with a discrete number of oligonucleotide strands for highly reproducible protein quantification by the dna proximity assay | |
| Navarro et al. | Caged luciferins enable rapid multicomponent bioluminescence imaging | |
| Zhang et al. | Identification of CD98 as a novel biomarker for HIV-1 permissiveness and latent infection | |
| ATE361378T1 (de) | Screeningverfahren auf anti-protease resistenz hiv-2-haltiger zellen, ausgehend von biologischen patientenproben | |
| Schmidt et al. | A model for the detection of clonality in marked hematopoietic stem cells | |
| ES2054769T3 (es) | Polipeptidos hiv-2 recombinantes. | |
| He et al. | Synthetic circuit-driven expression of heterologous enzymes for disease detection | |
| AU2395101A (en) | Method to evaluate the hiv drug sensitivity | |
| Potash et al. | Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif | |
| Wesalo et al. | Genetically Encoded Lysine Analogues with Differential Light Sensitivity for Activation of Protein Function | |
| Khan et al. | Contesting the evidence for− 1 frameshifting in immune-functioning CC chemokine receptor 5 (CCR5)–the HIV-1 co-receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |